Quarterly Results for second quarter and half year ended 30th September, 2025

Revenue DeclinePat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.9%Reaction day

₹128.90

prior close

₹130.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%+5.2% vs market

Pharmaceuticals peers, median of 157sector-0.2%+5.2% vs sector

On the reaction day the stock moved 5.2 pts more than Nifty Microcap 250 and 5.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.8

10m

+3.1

15m

+2.3

30m

+0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.9-0.3+5.2-0.2+5.2

Next day

+2.4+0.7+1.7+0.5+1.9

+3.8+0.6+3.2+0.6+3.3

-0.4+0.5-0.9+0.5-0.9

-0.2+1.1-1.3+0.4-0.6

+0.9+0.3+0.6-0.6+1.5

-0.7-0.2-0.5-1.1+0.4

15d

+0.0-2.2+2.3-2.1+2.1

-6.1-4.9-1.2-2.9-3.2

-9.2-7.5-1.8-5.8-3.4

-7.8-4.8-3.0-6.4-1.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Smruthi Organics reported unaudited results for Q2 FY26 and H1 FY26. Q2 revenue from operations rose 7.5% year-on-year to Rs. 3,159.52 lakhs (vs Rs. 2,939.10 lakhs in Q2 FY25), but H1 revenue declined about 10.7% to Rs. 5,068.73 lakhs versus Rs. 5,666.37 lakhs in H1 FY25. Net profit for Q2 jumped to Rs. 205.62 lakhs from Rs. 77.51 lakhs a year ago, and H1 swung from a Rs. 14.79 lakh loss to a Rs. 96.07 lakh profit. Q2 EPS stood at Rs. 1.80 versus Rs. 0.68. The API (bulk drugs) segment drove the turnaround, while the smaller Formulations division continued to post a loss of Rs. 16.72 lakhs in H1. Operating cash flow was strong at Rs. 1,703.48 lakhs in H1, and the company reduced both short-term and long-term borrowings.

Likely market impact

Sharp sequential and YoY recovery in profitability, better margins, and deleveraging are positive for shareholders, though the H1 topline decline and continued losses in Formulations may temper enthusiasm. Overall, the print is constructive for the stock.